Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management

Summary: Heatstroke is increasingly becoming a significant concern due to global warming. Systemic inflammation and coagulopathy are the two major factors that provoke life-threatening organ dysfunction in heatstroke. Dysregulated thermo-control induces cellular injury, damage-associated molecular p...

Full description

Bibliographic Details
Main Authors: Toshiaki Iba, Jean Marie Connors, Marcel Levi, Jerrold H. Levy
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:EClinicalMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022000062
_version_ 1818975779209347072
author Toshiaki Iba
Jean Marie Connors
Marcel Levi
Jerrold H. Levy
author_facet Toshiaki Iba
Jean Marie Connors
Marcel Levi
Jerrold H. Levy
author_sort Toshiaki Iba
collection DOAJ
description Summary: Heatstroke is increasingly becoming a significant concern due to global warming. Systemic inflammation and coagulopathy are the two major factors that provoke life-threatening organ dysfunction in heatstroke. Dysregulated thermo-control induces cellular injury, damage-associated molecular patterns release, hyperinflammation, and hypercoagulation with suppressed fibrinolysis to produce heatstroke-induced coagulopathy (HSIC). HSIC can progress to disseminated intravascular coagulation and multiorgan failure if severe enough. Platelet count, D-dimer, soluble thrombomodulin, and inflammation biomarkers such as interleukin-6 and histone H3 are promising markers for HSIC. In exertional heatstroke, the measurement of myoglobin is helpful to anticipate renal dysfunction. However, the optimal cutoff for each biomarker has not been determined. Except for initial cooling and hydration, effective therapy continues to be explored, and the use of antiinflammatory and anticoagulant therapies is under investigation. Despite the rapidly increasing risk, our knowledge is limited, and further study is warranted. In this review, we examine current information and what future efforts are needed to better understand and manage HSIC.
first_indexed 2024-12-20T16:01:22Z
format Article
id doaj.art-dcb8e6551742408681e63dbf7acf0d6d
institution Directory Open Access Journal
issn 2589-5370
language English
last_indexed 2024-12-20T16:01:22Z
publishDate 2022-02-01
publisher Elsevier
record_format Article
series EClinicalMedicine
spelling doaj.art-dcb8e6551742408681e63dbf7acf0d6d2022-12-21T19:34:17ZengElsevierEClinicalMedicine2589-53702022-02-0144101276Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient managementToshiaki Iba0Jean Marie Connors1Marcel Levi2Jerrold H. Levy3Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan; Corresponding author.Hematology Division Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United StatesDepartment of Medicine, University College London Hospitals NHS Foundation Trust, and Cardio-metabolic Programme-NIHR UCLH/UCL BRC London, United KingdomDepartment of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, United StatesSummary: Heatstroke is increasingly becoming a significant concern due to global warming. Systemic inflammation and coagulopathy are the two major factors that provoke life-threatening organ dysfunction in heatstroke. Dysregulated thermo-control induces cellular injury, damage-associated molecular patterns release, hyperinflammation, and hypercoagulation with suppressed fibrinolysis to produce heatstroke-induced coagulopathy (HSIC). HSIC can progress to disseminated intravascular coagulation and multiorgan failure if severe enough. Platelet count, D-dimer, soluble thrombomodulin, and inflammation biomarkers such as interleukin-6 and histone H3 are promising markers for HSIC. In exertional heatstroke, the measurement of myoglobin is helpful to anticipate renal dysfunction. However, the optimal cutoff for each biomarker has not been determined. Except for initial cooling and hydration, effective therapy continues to be explored, and the use of antiinflammatory and anticoagulant therapies is under investigation. Despite the rapidly increasing risk, our knowledge is limited, and further study is warranted. In this review, we examine current information and what future efforts are needed to better understand and manage HSIC.http://www.sciencedirect.com/science/article/pii/S2589537022000062HeatstrokeInflammationCoagulationEndothelial cellCell death
spellingShingle Toshiaki Iba
Jean Marie Connors
Marcel Levi
Jerrold H. Levy
Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
EClinicalMedicine
Heatstroke
Inflammation
Coagulation
Endothelial cell
Cell death
title Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
title_full Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
title_fullStr Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
title_full_unstemmed Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
title_short Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
title_sort heatstroke induced coagulopathy biomarkers mechanistic insights and patient management
topic Heatstroke
Inflammation
Coagulation
Endothelial cell
Cell death
url http://www.sciencedirect.com/science/article/pii/S2589537022000062
work_keys_str_mv AT toshiakiiba heatstrokeinducedcoagulopathybiomarkersmechanisticinsightsandpatientmanagement
AT jeanmarieconnors heatstrokeinducedcoagulopathybiomarkersmechanisticinsightsandpatientmanagement
AT marcellevi heatstrokeinducedcoagulopathybiomarkersmechanisticinsightsandpatientmanagement
AT jerroldhlevy heatstrokeinducedcoagulopathybiomarkersmechanisticinsightsandpatientmanagement